鑽石舞台

近日，代市長趙建軍深入高新區企業、院所、服務平台，並召開企業家座談會，專題調研推動無錫市集成電路產業高質量發展。

Wuxi Acting Mayor Zhao Jianjun recently inspected some enterprises, institutes, and service platforms that are engaged in the integrated circuit (IC) industry in the WND, and rallied entrepreneurs in a symposium to discuss and promote the high-quality development of Wuxi's IC industry.

趙建軍指出，集成電路產業是基礎性先導性產業，是無錫最具核心競爭力和持久爆發力影響力的產業。他強調，要認真落實市第十四次黨代會精神，堅持目標引領，搶抓發展機遇，圍繞產業延鏈、企業做強、人才集聚、技術突破，全力構建優質產業生態圈，加快打造具有國際競爭力的集成電路地標產業，奮力譜寫走在現代化建設最前列的無錫「芯」篇章。

Zhao pointed out that itis a basic leading industry with the greatest core competitiveness and long-lasting vigorous influence in Wuxi. He emphasized that efforts should focus on industrial chain extension, enterprise strengthening, talent gathering, technological breakthroughs, and creation of a high-quality industrial ecosystem. The goal is to accelerate the development of the IC industry into an internationally competitivelandmark.

近日，2021年度江蘇省工業和信息產業轉型升級專項資金（第三批）擬安排項目公示。高新區無錫濟煜山禾藥業股份有限公司獲評智能製造示範工廠建設項目。

A list ofthe proposed candidates for the 2021 Jiangsu provincial industrial and information industry transformation and upgrading special fundwas recently published. A Wuxi factoryowned byJemincare Shanhe Pharmaceutical Co Ltd, which is located in the WND and produceshigh-end preparations, has qualified as an intelligent manufacturing demonstration construction project and will receive fund support accordingly.

無錫濟煜山禾藥業股份有限公司是一家集科研、生產、銷售為一體的中西藥結合高新技術企業，是全國重點中藥廠之一。現有總資產19億元，經營品類7000多個，擁有系列國家一、二類新藥和國家級、省級高新技術產品，主要有「醒腦靜注射液」、「硫酸依替米星注射液」、「黃氏響聲丸」等，與5000餘家醫院建立合作關係，二甲以上醫院覆蓋率達70%。

Wuxi Jemincare Shanhe Pharmaceutical is one of the key Chinese medicine factories in the country and an accredited High & New-Technology Enterprise specialized in scientific research, production and sales of integrated Chinese and Western medicine. Currently, it possesses 1.9 billion yuan ($297.54 million)in assets, makesproducts inmore than 7,000 categories, and claims patentsfor a number ofnewnational Class I and Class II drugs and a series of high-tech products, including Etimicin Sulfate Injection and Huangshi Xiangsheng, used to treat chronic pharyngitis. The company has established cooperative relations with more than 5,000 hospitals, 70 percent of which are rated Grade-II Class-A.